Personalis Reports Q1 2026 Earnings: Clinical Test Growth Drives Strategic Revenue
Personalis (PSNL) delivered more than 7,800 clinical tests in the first quarter of 2026, reflecting strong sequential and year-over-year growth. Total revenue was $15.5 million with a significant decline from prior years due to strategic shifts away from lower-margin enterprise business toward higher-value biopharma MRD testing.
Topics: biopharma MRD revenue clinical testing revenue decline strategic shift